PHVS Stock Recent News

ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, will attend the 2023 Cantor Global Healthcare Conference, taking place in New York from September 26-28, 2023. Pharvaris management will participate in a fireside chat on Tuesday, September 26, from 2:10-2:40 p.m. ET.

ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the 18th German Allergy Congress, taking place in Bonn, Germany, from September 14-16, 2023.

ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, will attend the Morgan Stanley 21st Annual Global Healthcare Conference, taking place in New York from September 11-13, 2023. Morgan Conn, Ph.D., Chief Business Officer of Pharvaris, will participate in a fireside chat on Monday, September 11, at 3:35 p.m. ET.

ZUG, Switzerland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of three abstracts for presentation at the HAEi Regional Conference EMEA, taking place in Munich from September 1-3, 2023.

Pharvaris, a clinical-stage company, has reported a cash position of €135 million as of March 31, 2023, indicating an operational runway of approximately 18 months at current loss rates. The company's product pipeline, including PHVS416 and PHVS719, targets bradykinin-mediated diseases like HAE, with the FDA recently lifting a clinical hold on the IND application for deucrictibant. Despite promising developments, Pharvaris faces risks including potential off-target effects, unforeseen safety issues or insufficient efficacy in clinical trials, and regulatory hurdles.

Pharvaris has only one drug, deucrictibant, in its pipeline. Deucrictibant is being examined to treat hereditary angioedema (HAE), which can cause painful swelling.

ZUG, Switzerland, March 02, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that management will participate in two upcoming investor conferences in March:

ZUG, Switzerland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that management will present at the SVB Securities Global Biopharma Conference taking place virtually from February 14–16, 2023.

Pharvaris has a pipeline fully focused on HAE. Their molecule has a differentiated value proposition.

Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, has  announced positive top-line data from its RAPIDe-1 Phase 2 clinical study, sending its shares soaring in early trade. Releasing the results alongside its third-quarter financials, the Zug, Switzerland-based company said the data demonstrates statistically significant results of PHVS416 as an oral on-demand treatment for HAE attacks.